The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Treating CLL after venetoclax or BTK inhibitors
Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines the treatment options for chronic lymphocytic leukemia (CLL) patients who relapse after venetoclax or BTK inhibitors. Dr Mazyar specifically discusses how later lines ought to be considered early, and also mentions potential strategies the future could hold, such as CAR-T. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
